



Iowa Department of Human Services

Kim Reynolds
Governor

Adam Gregg
Lt. Governor

Jerry R. Foxhoven
Director

Iowa Medicaid Drug Utilization Review (DUR) Commission Meeting

August 2, 2017

Location: Learning Resource Center
3550 Mills Civic Parkway
West Des Moines, Iowa, 50265
Fairmeadows Room

Time: 9:30 a.m. – 1:30 p.m.

Final Agenda

1. Welcome & Introductions
 - a) New DUR Member Introductions
 - b) Commission Members and Staff
2. Commission Business
 - a) Approval of the Minutes
 - b) Annual Completion of Conflict of Interest Disclosure
 - c) Annual DUR Commission Chairperson and Vice Chairperson Elections
 - d) DHS Recommendation Letter – June 2017
 - e) [HF653](#) Process – Biologics and Genetically Targeted Drugs
 - f) [HF653](#) Report – Step Therapy Protocol for Prescription Drugs See [HF233](#)
3. IME Pharmacy Update
4. Fee-for-Service Program Prevalence Report Summary
5. MCO Prevalence Report Summary and Updates
 - a) United Healthcare Community Plan
 - b) AmeriHealth Caritas Iowa
 - c) Amerigroup
6. Public Comment* (See Conflict of Interest Disclosure Form)
7. Retrospective Claims Analysis
 - a) Concomitant Use of Benzodiazepines and Opioids
8. ProDUR Edits
 - a) Tramadol Age Edit

9. Prior Authorization

- a) Dupilumab (Dupixent) – Initial Review
- b) Buprinorphine/Naloxone – Initial Review
- c) Smoking Cessation Therapy, Oral & Nicotine Replacement Therapy – Initial Review
- d) High Dose Opioid (≥ 90 MME/day) – Additional Data
- e) Deflazacort (Emflaza) – Second Review
- f) Hepatitis C Treatments – Second Review
- g) Omalizumab (Xolair) – Second Review
- h) Crisaborole (Eucrisa) – Second Review
- i) Eluxadoline (Viberzi) – Second Review
- j) New to Market Drugs – Second Review

10. Miscellaneous

- a) DUR Digest Vol. 30, No. 1 – Initial Review
- b) MedWatch

11. Adjournment

*Individuals attending meetings of the DUR Commission shall have an opportunity to address the Commission. This opportunity will be granted once during the open portion of the meeting. In order to accommodate all interested parties, all speakers are requested to limit their comments to **5 minutes or less**. If you represent a drug manufacturer as an employee, as a contractor, as a member of the manufacturer's Speaker Bureau, or by any other means, we expect you to cover your individual product or entire product line in that five-minute time frame. Speakers who represent multiple manufacturers will share their 5 minutes with the other manufacturer representative(s) whose product they are speaking on.

www.iadur.org

For more information, contact the DUR Project Coordinator, Pamela Smith, R.Ph., at info@iadur.org or (515) 974-3131

*****Next Meeting October 4, 2017***
Mid-Iowa Council, Fred Maytag II Scout Center
6123 Scout Trail, Des Moines, IA 50321**